Scopus BioPharma (SCPS) Competitors $0.0003 0.00 (0.00%) As of 05/19/2025 09:33 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock SCPS vs. VAXX, SMFL, EVLO, GNCAQ, GNCA, ARDS, STAB, AMPE, CALA, and CMRAShould you be buying Scopus BioPharma stock or one of its competitors? The main competitors of Scopus BioPharma include Vaxxinity (VAXX), Smart for Life (SMFL), Evelo Biosciences (EVLO), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), Calithera Biosciences (CALA), and Comera Life Sciences (CMRA). These companies are all part of the "pharmaceutical products" industry. Scopus BioPharma vs. Vaxxinity Smart for Life Evelo Biosciences Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Statera Biopharma Ampio Pharmaceuticals Calithera Biosciences Comera Life Sciences Scopus BioPharma (NASDAQ:SCPS) and Vaxxinity (NASDAQ:VAXX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, earnings, valuation, profitability, dividends, media sentiment and institutional ownership. Do insiders and institutionals hold more shares of SCPS or VAXX? 82.9% of Vaxxinity shares are owned by institutional investors. 5.1% of Scopus BioPharma shares are owned by insiders. Comparatively, 64.1% of Vaxxinity shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has preferable valuation & earnings, SCPS or VAXX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScopus BioPharmaN/AN/A-$11.61MN/AN/AVaxxinityN/AN/A-$56.93M-$0.45-0.02 Does the MarketBeat Community favor SCPS or VAXX? Vaxxinity received 3 more outperform votes than Scopus BioPharma when rated by MarketBeat users. However, 100.00% of users gave Scopus BioPharma an outperform vote while only 38.46% of users gave Vaxxinity an outperform vote. CompanyUnderperformOutperformScopus BioPharmaOutperform Votes2100.00% Underperform VotesNo VotesVaxxinityOutperform Votes538.46% Underperform Votes861.54% Is SCPS or VAXX more profitable? Company Net Margins Return on Equity Return on Assets Scopus BioPharmaN/A N/A N/A Vaxxinity N/A N/A N/A Which has more volatility and risk, SCPS or VAXX? Scopus BioPharma has a beta of -0.29, meaning that its stock price is 129% less volatile than the S&P 500. Comparatively, Vaxxinity has a beta of -22.53, meaning that its stock price is 2,353% less volatile than the S&P 500. Does the media favor SCPS or VAXX? In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Vaxxinity'saverage media sentiment score. Company Overall Sentiment Scopus BioPharma Neutral Vaxxinity Neutral SummaryScopus BioPharma and Vaxxinity tied by winning 3 of the 6 factors compared between the two stocks. Get Scopus BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for SCPS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCPS vs. The Competition Export to ExcelMetricScopus BioPharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13,000.00$6.52B$5.37B$8.39BDividend YieldN/A2.65%5.22%4.10%P/E RatioN/A8.9226.8419.71Price / SalesN/A253.80392.34117.39Price / CashN/A65.8538.2534.62Price / BookN/A6.466.794.50Net Income-$11.61M$143.98M$3.23B$248.18M7 Day PerformanceN/A2.03%1.53%0.20%1 Month PerformanceN/A4.11%10.06%12.37%1 Year PerformanceN/A-2.87%16.72%7.04% Scopus BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCPSScopus BioPharmaN/A$0.00flatN/AN/A$13,000.00N/A0.009VAXXVaxxinityN/A$0.00-99.6%N/A-88.0%$25,000.00N/A0.0090Gap DownSMFLSmart for LifeN/A$0.00-82.9%N/A-100.0%$21,000.00$11.11M0.00110High Trading VolumeEVLOEvelo BiosciencesN/A$0.00flatN/AN/A$6,000.00N/A0.00120GNCAQGenocea BiosciencesN/AN/AN/AN/A$6,000.00N/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070Analyst ForecastARDSAridis PharmaceuticalsN/A$0.00flatN/A-99.8%$5,000.00$3.09M0.0030STABStatera BiopharmaN/A$0.00flatN/A-85.7%$5,000.00N/A0.0020AMPEAmpio PharmaceuticalsN/A$0.00+11.1%N/A-98.8%$3,000.00N/A0.0020Gap DownCALACalithera BiosciencesN/A$0.00+500.0%N/A-97.0%$3,000.00N/A0.0060Analyst ForecastGap UpCMRAComera Life SciencesN/A$0.00flatN/AN/A$3,000.00$1.00M0.002 Related Companies and Tools Related Companies Vaxxinity Competitors Smart for Life Competitors Evelo Biosciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Aridis Pharmaceuticals Competitors Statera Biopharma Competitors Ampio Pharmaceuticals Competitors Calithera Biosciences Competitors Comera Life Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCPS) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scopus BioPharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Scopus BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
